LeonardMKleinMD

Oncology • Chicago, IL

Hematologic Oncology

Director Stem Cell Transplantation at Lutheran General Hospital

Join to view full profile

Dr. Klein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Klein's full profile

Already have an account?

Office
25070 Network Pl
Chicago, IL 60673
Phone+1 847-585-7000

Fax+1 847-240-0622
Is this information wrong?

Education & Training

City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1982
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1978 - 1979
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1975 - 1978
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1975

Certifications & Licensure

CA State Medical License 1979 - Present
IL State Medical License 1982 - 2026
TX State Medical License 1977 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 Feb 01
Unknown status
Phase 1, Phase 2
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) Start of enrollment: 2012 Dec 11
Terminated
Phase 3
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma Start of enrollment: 2019 Dec 19
Recruiting
Phase 3
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer Start of enrollment: 2021 May 10
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

7 citations
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Loretta J Nastoupil, John Kuruvilla, Julio C Chavez, Fontanet Bijou, Thomas E Witzig, Armando Santoro, Ian W Flinn, Carola Boccomini, Vaishalee P Kenkre, Paolo Corradi...> ;Ejhaem. 2022 May 1
2 citations
Primary Gastric Choriocarcinoma: A Case Report of Early Successful Treatment Outcome.
Alyssa Ceilesh, Nasma K Majeed, Leonard M. Klein> ;JCO Oncology Practice. 2020 May 4
32 citations
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
David Andorsky, Kathryn S. Kolibaba, Sarit Assouline, Andres Forero-Torres, Vicky Jones, Leonard M. Klein, Dipti Patel-Donnelly, Mitchell R. Smith, Wei Ye, Wen Shi, Ch...> ;British Journal of Haematology. 2019 Jan 1
5 citations
E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
Sam J. Lubner, Yang Feng, Mary F. Mulcahy, Peter O'Dwyer, Guang Yu Giang, J. Louis Hinshaw, Dustin A. Deming, Leonard Klein, Ursina R. Teitelbaum, Jennifer Payne, Paul...> ;The Oncologist. 2018 Sep 1
9 citations
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
Alexa Cohen, Tanya M. Spektor, Laura Stampleman, Alberto Bessudo, Peter Rosen, Leonard M. Klein, Thomas B. S. Woliver, Marshall S. Flam, Shahrooz Eshaghian, Youram Nas...> ;British Journal of Haematology. 2018 Jan 1
49 citations
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory ...
Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan, Marshall T. Schreeder, Heather D. Brooks, Kathryn S. Kolibaba, Suzanne R. Fanning, Leonard M. Klein, Daniel R. Gr...> ;British Journal of Haematology. 2017 Feb 1
146 citations
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
Jeff P. Sharman, Michael J. Hawkins, Kathryn S. Kolibaba, Michael Boxer, Leonard M. Klein, Meihua Wu, Jing Hu, Steve Abella, Chris A. Yasenchak> ;Blood. 2015 Apr 9
46 citations
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide
Ivana N. Micallef, A. D. Ho, Leonard M. Klein, Sachin Marulkar, Pritesh J. Gandhi, P.A. McSweeney> ;Bone Marrow Transplantation. 2011 Oct 1
21 citations
High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large...
Jacob D. Bitran, Leonard M. Klein, Doreen Link, Jane Kosirog-Glowacki, Cynthia Stewart, David Raack, Pat Sheahan, Josephine Lisowski, Josie Rowen> ;Biology of Blood and Marrow Transplantation. 2003 Jun 1
27 citations
Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-hodgkin's lymphoma†
Lynn R. Kong, Cheng-Fang Huang, David Hakimian, Daina Variakojis, Leonard Klein, Timothy M. Kuzel, Leo I. Gordon, R N Connie Zanzig, B S Eric Wollins, Martin S. Tallman> ;Cancer. 1998 Mar 1
45 citations
Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high...
Jacob D. Bitran, Brian L. Samuels, Yolanda Trujillo, Leonard M. Klein, Linda Schroeder, James Martinec> ;Clinical Cancer Research. 1996 Sep 1
3 citations
A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells.
Roman-Unfer S, Jacob D. Bitran, Garrison L, Proeschel C, Stephen B. Hanauer, Schroeder L, Johnson L, Leonard M. Klein, Martinec J> ;Experimental Hematology. 1996 Jun 1
60 citations
Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Jacob D. Bitran, Brian L. Samuels, Leonard M. Klein, Stephen B. Hanauer, Johnson L, Martinec J, Harris E, Kempler J, White W> ;Bone Marrow Transplantation. 1996 Feb 1
59 citations
Iatrogenic superior vena cava syndrome. A new entity.
M Bertrand, Cary A. Presant, Leonard Klein, Edward P. Scott> ;Cancer. 1984 Jul 15
5 citations
Effects of amphotericin B with combination chemotherapy on response rates and on survival in non-small cell carcinoma of the lung.
Cary A. Presant, G E Metter, Multhauf P, M Bertrand, F F Chang, Leonard Klein, D Rappaport, B Kendregan, A Mackie> ;Cancer Treatment Reports. 1984 Apr 1
13 citations
Serum levels of carcinoembryonic antigen and a tumor-extracted carcinoembryonic antigen-related antigen in cancer patients.
John E. Shively, Vickie Spayth, Fong-Fu Chang, Gerald E. Metter, Leonard Klein, Cary A. Presant, Charles W. Todd> ;Cancer Research. 1982 Jun 1
6 citations
Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine.
Cary A. Presant, Denes Ae, Leonard Klein, Garrett S, G E Metter> ;Cancer Treatment Reports. 1980 Oct 1
Join now to see all

Lectures

Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018